SLC9A9 and Alzheimer disease: Of the novel variants, we found rs116726862 (SLC9A9 intron, increased Aβ40TX) was associated with higher Thal phase (P = 7.50E-03), increased CAA (P = 4.70E-02), and a trend for increased AD risk (P = 0.07), higher Braak stage (P = 0.07), and higher plasma p-Tau levels (P = 0.08).